[Breast neoplasms: predictive factors for endocrine therapy ].
Hayashi
Shin-ichi
S
Department of Medical Technology, Course of Health Science, School of Medicine, Tohoku University.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000209:etiology* / Q000628:therapy*; D003131:Combined Modality Therapy; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D004967:Estrogens / Q000502:physiology*; D005260:Female; D005544:Forecasting; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D011379:Prognosis; D011960:Receptors, Estrogen / Q000502:physiology*; D011980:Receptors, Progesterone; D015398:Signal Transduction / Q000235:genetics / Q000502:physiology; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D020847:Estrogen Receptor Modulators; D004967:Estrogens; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D007987:Gonadotropin-Releasing Hormone